论文部分内容阅读
目的观察津力达联合曲美他嗪治疗糖尿病心肌病的疗效。方法选取120例糖尿病心肌病患者,按随机、对照、单盲的方法分为2组:对照组60例,给予常规药物治疗;治疗组60例,在常规药物治疗基础上加用津力达联合曲美他嗪治疗,疗程均为半年。两组患者治疗前、后均分别评估患者心功能(纽约分级),以及检测左心室射血分数(LVEF%)、血中氨基末端脑钠肽前体(NT-pro BNP)、6min步行距离。结果治疗后,对照组上述指标有一定的改善,与治疗前比较,差异无统计学意义(P>0.05);而治疗组治疗后上述指标改善显著,与治疗前比较,差异有统计学意义(P<0.05);且治疗组与对照组治疗后比较,上述指标改善更显著,差异有统计学意义(P<0.05)。结论津力达联合曲美他嗪治疗,对改善糖尿病心肌病患者的心功能有一定疗效。
Objective To observe the therapeutic effect of trimetazidine combined with trimetazidine on diabetic cardiomyopathy. Methods 120 patients with diabetic cardiomyopathy were randomly divided into two groups according to randomized, controlled and single-blind methods: control group, 60 cases, given conventional drug treatment; treatment group, 60 cases, on the basis of conventional drug therapy combined with force of up to Trimetazidine treatment, treatment are six months. Patients’ heart function (New York classification), LVEF%, NT-pro BNP and 6-minute walking distance were evaluated before and after treatment. Results After treatment, the above indexes in the control group improved to a certain extent, compared with those before treatment, the difference was not statistically significant (P> 0.05); while the treatment group improved significantly after treatment, compared with before treatment, the difference was statistically significant P <0.05). Compared with the control group after treatment, the above indexes improved more significantly, the difference was statistically significant (P <0.05). Conclusions The combination of trimetazidine and trimetazidine has some effects on improving cardiac function in patients with diabetic cardiomyopathy.